(+)-1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol | 156692-01-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (+)-1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol
• 英文别名: 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethanol；(+/-)-1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol；(+/-)1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol；1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethanol
• CAS: 156692-01-2
• 化学式: C₁₇H₂₆O
• 分子量: 246.393
• InChiKey: XNMMWZBUYZDJOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (+)-1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol 、 甲基N-(2-苯甲酰基苯基)酪氨酸酯 、 偶氮二甲酸二乙酯 在 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 生成 (2S)-2-(2-Benzoylphenylamino)-3-(4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphtalen-2-yl)-ethoxy)-phenyl)-propionic acid methyl ester
  参考文献：
  名称：

  Compounds, their preparation and use

  摘要：

  公开了一种新的化合物，其化学式为I，其中R1、R2、R3、L、X和Y如说明书中所定义。这些化合物在治疗由核受体介导的疾病中具有用途，特别是视黄醇X受体（RXR）和过氧化物酶体增殖激活受体（PPAR）家族。这些疾病包括糖尿病和肥胖症。

  公开号：

  US06274608B1
• 作为产物：
  描述：

  1-(5,6,7,8-四氢-3,5,5,8,8-五甲基-2-萘基)乙烷-1-酮 在 LiAlH4 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (+)-1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalen-2-yl)ethanol
  参考文献：
  名称：

  Compounds, their preparation and use

  摘要：

  公开了一种新的化合物，其化学式为I，其中R1、R2、R3、L、X和Y如说明书中所定义。这些化合物在治疗由核受体介导的疾病中具有用途，特别是视黄醇X受体（RXR）和过氧化物酶体增殖激活受体（PPAR）家族。这些疾病包括糖尿病和肥胖症。

  公开号：

  US06274608B1

文献信息

• Treatment of mammals afflicted with tumors with compounds having RXR
  申请人：Allergan, Inc.

  公开号：US05399586A1

  公开（公告）日：1995-03-21

  Retinoid-like compounds which act as agonists of the RXR retinoid receptor sites induce apoptosis of tumor cells in cell cultures, and are used as drugs to treat tumors in mammals including humans. Compounds which are specific agonists of RXR receptors and also compounds which are agonists of both RAR and RXR agonist (pan-agonists) induce apoptosis, although the RXR agonist compounds are preferred as drugs to avoid undesirable side effects associated with RAR agonist activity. The RXR agonists compounds are administered to mammals afflicted with tumors in pharmaceutical compositions adapted for systemic topical or for intralesional administration. The range of concentration of the active ingredient RXR agonist compound in the pharmaceutical compositions is approximately between 0.001 and 5 percent by weight, and such that the composition delivers approximately 0.1 mg to 100 mg of the active ingredient per kg body weight of the patient, per day of treatment.

  类似视黄醇的化合物作为RXR视黄醇受体位点的激动剂，在细胞培养中诱导肿瘤细胞凋亡，并被用作药物治疗哺乳动物包括人类的肿瘤。既是RXR受体特异性激动剂的化合物，也是RAR和RXR激动剂（泛激动剂）的化合物均可诱导细胞凋亡，尽管RXR激动剂化合物更受欢迎作为药物，以避免与RAR激动剂活性相关的不良副作用。RXR激动剂化合物以适用于全身局部或病变部位内给药的制药组合物形式给哺乳动物患有肿瘤。药物组合物中活性成分RXR激动剂化合物的浓度范围大约在0.001％至5％之间，使组合物每日治疗时向患者的体重每千克输送大约0.1毫克至100毫克的活性成分。
• Tetrahydronaphthyl and thiazole, oxazole or imidazole substituted ethene
  申请人：Allergan, Inc.

  公开号：US05475113A1

  公开（公告）日：1995-12-12

  Compounds of the formula ##STR1## as herein defined, have retinoid-like activity and are substantially non-teratogenic and non-irritating to the skin.

  公式为##STR1##的化合物具有类视黄醇活性，并且对皮肤基本上没有致畸和刺激作用。
• Method of treatment with compounds having retinoid-like activity and
  申请人：Allergan, Inc.

  公开号：US05324840A1

  公开（公告）日：1994-06-28

  Compounds that provide non-teratogenic effects and lack irritation to the skin are shown in the formula below where the partially drawn ring signifies an aromatic ring which may be carbocyclic or heteroaromatic, 6-membered or 5-membered, and may be condensed with another ring. R.sub.1 is lower alkyl, Cl, Br, or I, R.sub.2 is H, lower alkyl, Cl, Br, or I, and R.sub.3 is lower alkyl, Cl, Br, I, or is an ether, thioether, ester, thioester, amine or substituted amine group. ##STR1##

  下面的公式展示了提供非致畸效应且不刺激皮肤的化合物，其中部分绘制的环表示芳香环，可以是碳环或杂环，6元或5元，并且可以与另一个环融合。R.sub.1代表低碳基，Cl，Br或I，R.sub.2代表H，低碳基，Cl，Br或I，R.sub.3代表低碳基，Cl，Br，I，或是醚，硫醚，酯，硫酯，胺或取代胺基团。##STR1##
• Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
  申请人：Allergan, Inc.

  公开号：US06627652B1

  公开（公告）日：2003-09-30

  Process of treatment of mammals, including humans to treat diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid receptor sites in preference to the RAR retinoid receptor sites. A compound is defined to be a selective agonist of the RXR receptor site if the compound is at least approximately ten times more effective as an agonist in the RXR receptor sites than in the RAR receptor sites.

  揭示了哺乳动物（包括人类）治疗通常使用类视黄醇化合物治疗的疾病或状况的过程，其中包括含有一种活性化合物的药物组合物，该活性化合物是RXR视黄醇受体位点的选择性激动剂，优先于RAR视黄醇受体位点。如果化合物在RXR受体位点中作为激动剂的效果至少比在RAR受体位点中高出约十倍，则定义该化合物为RXR受体位点的选择性激动剂。
• Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
  申请人：Allergan, Inc.

  公开号：US06624188B1

  公开（公告）日：2003-09-23

  A process and pharmaceutical compositions for treating several diseases and conditions which are normally treatable with retinoid like compounds are disclosed where the compound used for the treatment are substantially non-teratogenic and not irritant to the skin. The process is useful for treating female mammals, including humans, who are pregnant or in the child bearing age. An important partial structural feature of the compounds which provides the non-teratogenic effect and lack of irritation of skin is shown by the formula where the partially drawn ring signifies an aromatic ring which may be carbocyclic or heteroaromatic, 6-membered or 5-membered, and may be condensed with another ring. R1 is lower alkyl, Cl, Br, or I, R2 is H, lower alkyl, Cl, Br, or I, and R3 is lower alkyl, Cl, Br, I, or is an ether, thioether, ester, thioester, amine or substituted amine group.

  本发明涉及一种用于治疗多种疾病和病况的过程和药物组合物，这些疾病和病况通常可以用类视黄醇类化合物进行治疗。用于治疗的化合物是基本上非致畸形和不刺激皮肤的。该过程可用于治疗包括人在内的孕妇或生育年龄的雌性哺乳动物。化合物的一个重要部分结构特征是由式表示的，其中部分绘制的环表示可以是碳环或杂环的芳香环，6元环或5元环，并且可以与另一个环融合。R1是低碳基，Cl，Br或I，R2是H，低碳基，Cl，Br或I，R3是低碳基，Cl，Br，I，或是醚，硫醚，酯，硫酯，胺或取代胺基团。